Jürgen Floege

Nov 7, 2024 | radcliffecvrm.com | Andrew Coats |Brad H Rovin |Jürgen Floege |Muthiah Vaduganathan

Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease. In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).